“BBV154” A Bharat Biotech’s Intranasal Vaccine vaccine

ForumIAS announcing GS Foundation Program for UPSC CSE 2025-26 from 19 April. Click Here for more information.

ForumIAS Answer Writing Focus Group (AWFG) for Mains 2024 commencing from 24th June 2024. The Entrance Test for the program will be held on 28th April 2024 at 9 AM. To know more about the program visit: https://forumias.com/blog/awfg2024

What is the news?
An expert body is looking into Bharat Biotech’s application for testing its  Covid-19 vaccine, BBV154. This is an Intranasal Vaccine.

What is Intranasal Vaccine?

  • Vaccines are administered as injectable shots into the muscles(intramuscular). Or the tissue just between the skin and the muscles(subcutaneous).
  • However, with intranasal vaccines, the solution is sprayed into the nostrils and inhaled instead of injecting it.

Benefits of Intranasal Vaccine:

  • The nasal route has excellent potential for vaccination due to the organized immune systems of the nasal mucosa.
    • It is non-invasive, Needle-free.
    • Ease of administration – does not require trained health care workers.
    • Elimination of needle-associated risks (injuries and infections).
    • High compliance (Ideally suits for children and adults).
    • Reduces the overall cost of a vaccination drive as for example BBV154 requires a single-dose regimen.

Potential Setbacks of Intranasal Vaccine:

  • Past attempts to develop intranasal vaccines, including for measles flu, have not been very successful.
  • These vaccines use live, weakened viruses, but have never cleared clinical trials.
  • Only a live attenuated influenza flu vaccine has been licensed through this route of delivery.

Source: Indian Express

Print Friendly and PDF
Blog
Academy
Community